Arbutus Biopharma Corporation ABUS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 81.7%+353pp | -271%+49.5pp | -320.4%+66.1pp | -386.5%+904pp | -1,290.9%-54.1pp | |
| Net margin | 84%+322pp | -237.9%+51.6pp | -289.4%+62.5pp | -351.9%+844pp | -1,195.9%-62.8pp | |
| EBITDA margin | 81.8%+350pp | -267.8%+47.8pp | -315.7%+64.2pp | -379.9%+890pp | -1,269.5%-55.4pp | |
| Returns | ||||||
| Return on equity | 94.7%+133pp | -38.5%+7.4pp | -45.9%+6.9pp | -52.8%+26.2pp | -79%-10.3pp | |
| Return on assets | 81.5%+111pp | -29.6%+5.9pp | -35.5%+5.7pp | -41.2%+16.1pp | -57.3%-6.6pp | |
| Return on invested capital | 111.6%+174pp | -62.7%+8.0pp | -70.7%+39.7pp | -110.4%+31.5pp | -141.9%-35.8pp | |
| Efficiency | ||||||
| Asset turnover | 1×+0.8× | 0.1×0.0× | 0.1×0.0× | 0.1×+0.1× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 54.3×+38.5× | 15.7×-3.1× | 18.8×-1.7× | 20.5×+14.5× | 6×-2.1× | |
| Quick ratio | 54.3×+38.5× | 15.7×-3.1× | 18.8×-1.7× | 20.5×+14.5× | 6×-2.1× | |
| Cash ratio | 4.6×+1.6× | 3×-1.3× | 4.3×-3.1× | 7.4×+5.5× | 1.9×-0.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -0.1×— | —— | —— | —— | —— | |
| Interest coverage | 1,819.2×+2,213× | -393.4×+36.0× | -429.4×+88.7× | -518.1×+165× | -683.1×-126× | |
| Per Share | ||||||
| Book value per share | $1.33+233% | $0.40-1.0% | $0.40-6.4% | $0.43+3.9% | $0.42-20.9% | |
| Valuation | ||||||
| Market capitalization | $881.02M+32.6% | $925.08M+6.3% | $870.31M+34.8% | $645.45M-3.4% | $668.27M+7.8% | |
| Enterprise value | $857.94M+36.6% | $907.82M+6.9% | $848.83M+39.4% | $609.12M-3.7% | $632.38M+8.2% | |
| Price / earnings | 5.5×— | —— | —— | —— | —— | |
| Price / sales | 4.6×-99.1× | 65.7×+6.1× | 59.6×+17.7× | 41.9×-62.5× | 104.4×+4.0× | |
| Price / book | 3.3×-5.0× | 12.1×+0.8× | 11.2×+3.5× | 7.8×-0.7× | 8.4×+2.1× | |
| EV / EBITDA | 5.4×— | —— | —— | —— | —— | |
| EV / sales | 4.4×-92.6× | 64.5×+6.3× | 58.1×+18.6× | 39.5×-59.3× | 98.8×+4.0× | |
| Earnings yield | 18.4%+30.1pp | -3.6%+1.2pp | -4.9%+3.5pp | -8.4%+3.1pp | -11.5%-0.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Arbutus Biopharma Corporation's ratios come from?
- Every ratio is computed from Arbutus Biopharma Corporation's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
